FGFs/FGFRs-dependent Signalling in Regulation of Steroid Hormone Receptors - Implications for Therapy of Luminal Breast Cancer

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2019 May 31

PMID 31142340

Citations 27

Authors

Dominika Piasecka

Marcin Braun

Kamila Kitowska

Kamil Mieczkowski

Radzislaw Kordek

Rafal Sadej

Hanna Romanska

Affiliations

Soon will be listed here.

Abstract

Stromal stimuli mediated by growth factor receptors, leading to ligand-independent activation of steroid hormone receptors, have long been implicated in development of breast cancer resistance to endocrine therapy. Mutations in fibroblast growth factor receptor (FGFR) genes have been associated with a higher incidence and progression of breast cancer. Increasing evidence suggests that FGFR-mediated interaction between luminal invasive ductal breast carcinoma (IDC) and its microenvironment contributes to the progression to hormone-independence. Therapeutic strategies based on FGFR inhibitors hold promise for overcoming resistance to the ER-targeting treatment. A series of excellent reviews discuss a potential role of FGFR in development of IDC. Here, we provide a concise updated summary of existing literature on FGFR-mediated signalling with an emphasis on an interaction between FGFR and estrogen/progesterone receptors (ER/PR) in IDC. Focusing on the regulatory role of tumour microenvironment in the activity of steroid hormone receptors, we compile the available functional data on FGFRs-mediated signalling, as a fundamental mechanism of luminal IDC progression and failure of anti-ER treatment. We also highlight the translational value of the presented findings and summarize ongoing oncologic clinical trials investigating FGFRs inhibition in interventional studies in breast cancer.

Citing Articles

Prognostic value of in ER-positive breast cancer is influenced by the profile of stromal gene expression: an analysis based on TCGA data.

Solek J, Nowicka Z, Fendler W, Sadej R, Romanska H, Braun M Contemp Oncol (Pozn). 2025; 28(4):341-349.

PMID: 39935756 PMC: 11809570. DOI: 10.5114/wo.2024.147003.

Lower mRNA Expression and Higher Levels of in HER2-Positive Breast Cancer.

Dix-Peek T, Dickens C, Valcarcel J, Duarte R Biology (Basel). 2024; 13(11).

PMID: 39596875 PMC: 11591975. DOI: 10.3390/biology13110920.

FGFR2-triggered autophagy and activation of Nrf-2 reduce breast cancer cell response to anti-ER drugs.

Gorska-Arcisz M, Popeda M, Braun M, Piasecka D, Nowak J, Kitowska K Cell Mol Biol Lett. 2024; 29(1):71.

PMID: 38745155 PMC: 11092031. DOI: 10.1186/s11658-024-00586-6.

Heterogeneity in precision oncology.

Tomasik B, Garbicz F, Braun M, Bienkowski M, Jassem J Camb Prism Precis Med. 2024; 2:e2.

PMID: 38549846 PMC: 10953762. DOI: 10.1017/pcm.2023.23.

Chemotherapeutic Activity of Imidazolium-Supported Pd(II) -Vanillylidene Diaminocyclohexane Complexes Immobilized in Nanolipid as Inhibitors for HER2/neu and FGFR2/FGF2 Axis Overexpression in Breast Cancer Cells.

Awaji A, Rizk M, Alsaiari R, Alqahtani N, Al-Qadri F, Alkorbi A Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139837 PMC: 10747766. DOI: 10.3390/ph16121711.

References

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

Ruohola J, Viitanen T, Valve E, Seppanen J, Loponen N, Keskitalo J . Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res. 2001; 61(10):4229-37. View

Sleeman M, Fraser J, McDonald M, Yuan S, White D, Grandison P . Identification of a new fibroblast growth factor receptor, FGFR5. Gene. 2001; 271(2):171-82. DOI: 10.1016/s0378-1119(01)00518-2. View

Shen T, Horwitz K, Lange C . Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol Cell Biol. 2001; 21(18):6122-31. PMC: 87329. DOI: 10.1128/MCB.21.18.6122-6131.2001. View

Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19):10869-74. PMC: 58566. DOI: 10.1073/pnas.191367098. View

Mailleux A, Spencer-Dene B, Dillon C, Ndiaye D, Savona-Baron C, Itoh N . Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo. Development. 2002; 129(1):53-60. DOI: 10.1242/dev.129.1.53. View

Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M . Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 2002; 62(3):840-7. View

Labriola L, Salatino M, Proietti C, Pecci A, Coso O, Kornblihtt A . Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells. Mol Cell Biol. 2003; 23(3):1095-111. PMC: 140689. DOI: 10.1128/MCB.23.3.1095-1111.2003. View

Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills G . Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity.... Mol Endocrinol. 2003; 17(4):575-88. DOI: 10.1210/me.2002-0318. View

10.

Qiu M, Olsen A, Faivre E, Horwitz K, Lange C . Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors. Mol Endocrinol. 2003; 17(4):628-42. DOI: 10.1210/me.2002-0378. View

11.

Ballare C, Uhrig M, Bechtold T, Sancho E, Di Domenico M, Migliaccio A . Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol. 2003; 23(6):1994-2008. PMC: 149459. DOI: 10.1128/MCB.23.6.1994-2008.2003. View

12.

Bardou V, Arpino G, Elledge R, Osborne C, Clark G . Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003; 21(10):1973-9. DOI: 10.1200/JCO.2003.09.099. View

13.

Qiu M, Lange C . MAP kinases couple multiple functions of human progesterone receptors: degradation, transcriptional synergy, and nuclear association. J Steroid Biochem Mol Biol. 2003; 85(2-5):147-57. DOI: 10.1016/s0960-0760(03)00221-8. View

14.

Clarke R, Liu M, Bouker K, Gu Z, Lee R, Zhu Y . Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 2003; 22(47):7316-39. DOI: 10.1038/sj.onc.1206937. View

15.

Lin E, Pollard J . Macrophages: modulators of breast cancer progression. Novartis Found Symp. 2004; 256:158-68. View

16.

Russo J, Russo I . Development of the human breast. Maturitas. 2004; 49(1):2-15. DOI: 10.1016/j.maturitas.2004.04.011. View

17.

Wyckoff J, Wang W, Lin E, Wang Y, Pixley F, Stanley E . A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004; 64(19):7022-9. DOI: 10.1158/0008-5472.CAN-04-1449. View

18.

Nelson K, Bidwell M, Curtis S, Washburn T, McLachlan J, Korach K . Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc Natl Acad Sci U S A. 1992; 89(10):4658-62. PMC: 49142. DOI: 10.1073/pnas.89.10.4658. View

19.

Gee J, Robertson J, Gutteridge E, Ellis I, Pinder S, Rubini M . Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer. 2005; 12 Suppl 1:S99-S111. DOI: 10.1677/erc.1.01005. View

20.

Arpino G, Weiss H, Lee A, Schiff R, De Placido S, Osborne C . Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005; 97(17):1254-61. DOI: 10.1093/jnci/dji249. View